Tocilizumab is a humanized monoclonal antibody to the interleukin-6 (IL-6) receptor that is used in the therapy of rheumatoid arthritis and other autoinflammatory conditions. Tocilizumab commonly causes mild serum aminotransferase elevations that are usually short lived and asymptomatic, but has also been linked to rare instances of clinically apparent liver injury with jaundice and occasional reactivation of hepatitis B. It is grouped under the following drug class(es): Biologics, Immunosuppressants and Kinase inhibitors. Its therapeutic use is listed as anti-inflammatories and antirheumatic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Actemra, Atlizumab and Roactemra. Its PubChem SID is 517913830.
Tocilizumab
| CAS No | 375823-41-9 |
|---|---|
| Molecular Formula | C6428H9976N1720O2018S42 |
| Molecular Weight | 149,000 g/mol |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tocilizumab is a humanized monoclonal antibody to the interleukin-6 (IL-6) receptor that is used in the therapy of rheumatoid arthritis and other autoinflammatory conditions.
The listed CAS number is 375823-41-9.
The listed molecular formula is C6428H9976N1720O2018S42.
The listed molecular weight is 149,000 g/mol.
N/A.
The source lists Actemra, Atlizumab and Roactemra.